Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals' Non-Current Assets history runs 10 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Non-Current Assets fell 6.06% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.1 billion (down 8.16% YoY), while the FY2025 annual figure was $1.8 billion, down 7.66% from the prior year.
• Non-Current Assets was $1.7 billion for Q1 2026 at Amneal Pharmaceuticals, down from $1.8 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $2.5 billion in Q1 2022 to a low of $1.7 billion in Q1 2026.
• Historically, Non-Current Assets has averaged $2.1 billion across 5 years, with a median of $2.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets gained 4.12% in 2022, then declined 12.7% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $2.4 billion in 2022, then slipped by 12.26% to $2.1 billion in 2023, then declined by 8.64% to $1.9 billion in 2024, then decreased by 7.66% to $1.8 billion in 2025, then retreated by 1.4% to $1.7 billion in 2026.
• The last three Non-Current Assets figures came in at $1.7 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.